Neuroleptic Malignant Syndrome: An Undiagnosed Case

Volume 2 - Issue 5

Haris Chaudhry¹*, Cesar Figueroa², Mohammad Alasker², Saher Aslam³, Usama Nasir⁴ and Ibrar Anjum⁵

Received: August 26, 2019;   Published: September 04, 2019

DOI: 10.32474/SJPBS.2019.02.000147

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Neuroleptic malignant syndrome (NMS) was first described six decades ago after the introduction of neuroleptic drugs for the treatment of psychotic disorders [1]. NMS is an infrequent yet potentially fatal adverse effect of the neuroleptic class of antipsychotic medications. Signs of NMS include fever, muscular rigidity, altered mental status, elevation of creatine kinase (CK) with its incidence ranging between 0.07% to 0.2% [2-3]. NMS is possible with all neuroleptics. It can be easily recognized in its classic form but the lack of a specific diagnostic criteria along with its rare occurrence has limited further study in this field [4]. NMS is not generally considered dose-dependent and can occur within the therapeutic dose range of the antipsychotic drugs [5]. The frequency of NMS ranges from 0.07 to 2.2%. Its pathophysiology is not clearly understood but the blockade of dopamine receptors appears to be the central mechanism [6]

Background| Objective| Case Report| Discussion| Conclusion| References|